Kadmon Holdings, Inc. Loss Submission Form

See If You Qualify For Monetary Reward

Enter your details and we will calculate your loss for you

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

    Review Our Privacy Policy

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a KDMN class action lawsuit has been filed on behalf of investors who purchased Kadmon Holdings, Inc. (KDMN) securities between October 1, 2020 and March 10, 2021. For more on the KDMN Lawsuit please contact us today.

    According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

    If you suffered a loss in you have until June 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.